Pfizer Inc.
PFEHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, Pfizer Inc. (PFE) is listed under Drug Manufacturers - General. The $142.77B market capitalization puts PFE squarely in large-cap range for its industry. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Market Cap
$142.77B
Beta
0.31
P/E (TTM)
19.12
P/E (Fwd)
8.84
EPS (TTM)
$1.31
EPS (Fwd)
$2.83
ROE
8.3%
ROA
5.7%
Cash
$13.08B
Total Debt
$64.73B
Free CF
$12.38B
52W Change
2.4%
Annual Financials
Cash vs Debt
Pfizer Inc. carries $64.73B in total debt against $13.08B in cash reserves — debt is roughly 4.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $12.38B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 8.3% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $101.17B (2022) to $62.58B (2025), a 38% decline worth watching.
With a beta below 0.7, Pfizer Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pfizer Inc. and its sector.